Michael Pollock's questions to Nyxoah SA (NYXH) leadership • Q2 2025
Question
Michael Pollock from Wolfe Research asked for confirmation of Nexeo's U.S. pricing strategy relative to its competitor and inquired about what level of commitment, such as a share of patient wallet, the company asks from surgeons it trains on the GENEO system.
Answer
CEO Olivier Talman confirmed that the company will use the same CPT code and follow the associated pricing strategy, implying price parity with its competitor. Regarding surgeon commitment, he explained that instead of asking for a market share percentage, Nexeo requires physicians to identify five qualified patient cases before they are trained, ensuring they are prepared to begin implanting immediately and move through the learning curve.